{
"id":"mk19_b_rm_s8",
"subspecialtyId":"rm",
"title":"Sjögren Syndrome",
"jsonContent":{
"type":"section",
"id":"mk19_b_rm_s8",
"title":{
"__html":"Sjögren Syndrome"
},
"titleNode":{
"type":"section-title",
"hlId":"dd4b0f",
"children":[
"Sjögren Syndrome"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s8_1",
"title":{
"__html":"Epidemiology and Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"c25aa6",
"children":[
"Epidemiology and Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"3a4101",
"children":[
"Sjögren syndrome is a systemic autoimmune exocrinopathy primarily affecting salivary and lacrimal glands. The condition is female predominant, with a female-to-male ratio between 6 and 9 to 1. Sjögren syndrome most commonly presents in the fifth and sixth decades of life, but patients of any age may be affected; a pediatric variant is also recognized. Primary Sjögren syndrome occurs in isolation; secondary Sjögren syndrome develops with other rheumatologic diseases, most commonly rheumatoid arthritis and systemic lupus erythematosus. Whereas the primary form is uncommon (ranging from 0.5 to 5 patients/1000), secondary Sjögren syndrome is often observed (10%-30%) among populations with predisposing rheumatologic conditions. Sjögren syndrome is thought to result from activation of mucosal epithelial cells by unknown stimuli. This, in turn, leads to tonic activation of the innate and adaptive immune systems, including extensive influx of lymphocytes into exocrine glands. The resulting epithelial and obliterative damage impairs the ability to produce or deliver secretions."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s8_2",
"title":{
"__html":"Clinical Manifestations"
},
"titleNode":{
"type":"section-title",
"hlId":"65ac9d",
"children":[
"Clinical Manifestations"
]
},
"children":[
{
"type":"p",
"hlId":"ea8a4a",
"children":[
"The most common presentation of Sjögren syndrome is sicca, consisting of ocular and oral dryness. Patients report gritty eyes or a foreign body sensation. Oral dryness can cause difficulty eating unmoistened food and increases the risk for dental caries. Symmetric parotid and lacrimal swelling can occur. Other exocrine glands can be involved, leading to skin and vaginal dryness. Pancreatic involvement has been reported."
]
},
{
"type":"p",
"hlId":"78d4b7",
"children":[
"Extraglandular manifestations may occur in some patients ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t22",
"wrapId":"1",
"children":[
"Table 22"
]
}
]
},
")"
]
},
". Arthralgia and fibromyalgia are common, but nonerosive arthritis in the absence of rheumatoid arthritis is uncommon. Other common extraglandular manifestations include fatigue and Raynaud phenomenon. Both peripheral and central nervous system involvement may be seen, although the former is more common. The typical peripheral nervous system manifestation is axonal polyneuropathy. Central nervous system involvement often presents as demyelinating disease, such as optic neuritis, transverse myelitis, or a multiple sclerosis–like presentation. Cutaneous, pulmonary, and kidney disease are relatively rare. Nonspecific laboratory findings include hypocomplementemia, hypergammaglobulinemia, leukopenia, and anemia of inflammation."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_rm_t22"
]
},
{
"type":"p",
"hlId":"d44d80",
"children":[
"Patients with Sjögren syndrome are at increased risk for non-Hodgkin lymphoma compared with the general population. Estimates suggest as much as a 44-fold increased risk for mucosal-associated lymphoid tissue lymphoma; this increase presumably results from an elevated risk for lymphomatous transformation due to chronic activation of tissue lymphocytes. Clinical features conferring a higher risk include lymphadenopathy, recurrent parotid gland swelling, monoclonal gammopathy, depressed C4 complement, and decreased rheumatoid factor if titer is elevated at baseline. About 5% of patients with Sjögren syndrome develop lymphoma over time, usually within the first decade after diagnosis."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s8_3",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"a28025",
"children":[
"An evaluation for Sjögren syndrome is typically triggered when the patient reports symptoms of ocular or oral dryness. It requires objective confirmation of exocrinopathy along with demonstration of autoimmunity ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t23",
"wrapId":"2",
"children":[
"Table 23"
]
}
]
}
]
},
" shows validated classification criteria). Ophthalmic dryness can be assessed by using the Schirmer test, in which a strip of filter paper is placed under the lower eyelid and wetting is measured; less than 5 mm of wetting in 5 minutes indicates dryness. More formally, dryness and corneal damage are ascertained with slit-lamp examination by an ophthalmologist. Topical staining may be used to identify injury and fissures in the cornea. Dry mouth is assessed by direct examination, with dental caries and a lack of saliva suggesting the diagnosis. Measurement of salivary flow, or sialometry, should ideally be performed to determine whether true dryness is present (and to show ductal architecture). However, this is rarely done because it requires special equipment that is not available in most settings. Other forms of imaging (e.g., CT, gallium scanning) are not generally helpful but may rarely be useful in defining organ involvement."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_rm_t23"
]
},
{
"type":"p",
"hlId":"1bac3c",
"children":[
"Multiple autoantibodies may be found in Sjögren syndrome, but none are independently diagnostic. Antinuclear antibodies and/or rheumatoid factor are often present at high titers; their coexpression is more suggestive of Sjögren syndrome than is positivity of only one. The presence of anti-Ro/SSA autoantibodies is specific in primary Sjögren syndrome but less so in secondary Sjögren syndrome because these antibodies are also common in systemic lupus erythematosus. Anti-La/SSB autoantibodies are characteristic of Sjögren syndrome but are not included in formal classification criteria. When initial evaluation is uninformative, a lip (minor salivary gland) biopsy should be considered. Characteristic histologic features include aggregate foci (>50 cells/aggregate) of CD4 T cells, B cells, and plasma cells surrounding secretory ducts."
]
},
{
"type":"p",
"hlId":"668ce8",
"children":[
"The differential diagnosis of Sjögren syndrome typically relates to the presence of sicca and/or parotid and lacrimal enlargement. Sarcoidosis, IgG4-related disease, granulomatosis with polyangiitis, lymphoma, and infection (such as mumps, hepatitis C virus infection, and HIV infection) may be associated with similar findings. Ocular and oral dryness may also occur with aging, in other disease states (such as rheumatoid arthritis), or as an adverse effect of medications or treatment (such as antidepressants and antihistamines or radiation of the head and neck). Unilateral or single enlargement of a gland should raise concern for obstruction or malignancy."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s8_4",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"57faf2",
"children":[
"Management of sicca centers on preserving moisture and relieving symptoms. Eye dryness is treated with over-the-counter artificial tears, gels, and ointments; for refractory or more severe symptoms, topical cyclosporine or a small-molecule integrin antagonist may be added. Plugging the lacrimal ducts to promote tear retention is widely performed, but clinical trials have not shown its effectiveness. For oral dryness, first-line treatment in patients with less severe symptoms should be nonpharmacologic salivary stimulation, both with gustatory stimulants (e.g., sugar-free candy) and mechanical stimulants (e.g., sugar-free gum)."
]
},
{
"type":"p",
"hlId":"a629bb",
"children":[
"Pharmacologic therapies should be reserved for moderate or severe oral dryness. These include the muscarinic agonists pilocarpine and cevimeline, which may not be well tolerated; they are also contraindicated in narrow-angle glaucoma. Artificial saliva may be used for severe dysfunction, but its effects are so transient that most patients do not find it useful. Meticulous dental care is essential to prevent gingivitis and dental decay, regardless of symptom severity. Vaginal symptoms may be treated with topical lubricants or estrogen."
]
},
{
"type":"p",
"hlId":"8d0dbf",
"children":[
"Active extraglandular autoimmune disease should be treated with systemic therapies. In most cases, glucocorticoids may be considered as a first-line option, but only at the minimum dose and length of time necessary to control the active disease. Immunomodulatory/immunosuppressive (e.g., hydroxychloroquine, methotrexate, cyclophosphamide) and biologic (e.g., anti–B cell therapy with rituximab or belimumab) agents should be considered for second- or third-line therapy, or for glucocorticoid sparing. To the extent possible, decisions should be tailored to severity and the organ or organs affected (e.g., pneumonitis, central nervous system disease). Musculoskeletal pain is common in Sjögren syndrome but should not be treated with immunomodulatory or biologic therapy unless there is objective evidence of active inflammatory arthritis. Myalgia and arthralgia, along with chronic nonspecific pain, should be treated symptomatically."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s8_5",
"title":{
"__html":"Prognosis"
},
"titleNode":{
"type":"section-title",
"hlId":"6781bd",
"children":[
"Prognosis"
]
},
"children":[
{
"type":"p",
"hlId":"1ab50b",
"children":[
"The prognosis for primary Sjögren syndrome is favorable, with no overall increase in mortality. Management of sicca reduces the risk for corneal damage or tooth loss. In rare instances, end-organ involvement can be life-threatening. Secondary Sjögren syndrome may be associated with significant morbidity from the primary condition."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"c7da67",
"children":[
"Sjögren syndrome is an autoimmune exocrinopathy affecting salivary and lacrimal glands; the most common presentation is sicca (dryness of the eyes and/or mouth)."
]
},
{
"type":"keypoint",
"hlId":"6587f9",
"children":[
"Patients with Sjögren syndrome are at increased risk for non-Hodgkin lymphoma."
]
},
{
"type":"keypoint",
"hlId":"8d87df",
"children":[
"A diagnosis of Sjögren syndrome is typically triggered by the patient's report of ocular and oral dryness and requires objective confirmation of exocrinopathy, along with demonstration of autoimmunity."
]
},
{
"type":"keypoint",
"hlId":"44ad3f",
"children":[
"In patients with Sjögren syndrome, management of sicca centers on preserving moisture and relieving symptoms; extraglandular involvement is treated with immunosuppression."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s8_6",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Mariette X, Criswell LA. Primary Sjögren's syndrome. N Engl J Med. 2018;378:931-939. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29514034",
"target":"_blank"
},
"children":[
"PMID: 29514034"
]
},
" doi:10.1056/NEJMcp1702514"
]
},
{
"type":"reference",
"children":[
"Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al; EULAR-Sjögren Syndrome Task Force Group. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79:3-18. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31672775",
"target":"_blank"
},
"children":[
"PMID: 31672775"
]
},
" doi:10.1136/annrheumdis-2019-216114"
]
},
{
"type":"reference",
"children":[
"Sandhya P, Kurien BT, Danda D, et al. Update on pathogenesis of Sjogren's syndrome. Curr Rheumatol Rev. 2017;13:5-22. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27412602",
"target":"_blank"
},
"children":[
"PMID: 27412602"
]
},
" doi:10.2174/1573397112666160714164149"
]
},
{
"type":"reference",
"children":[
"Shiboski CH, Shiboski SC, Seror R, et al; International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76:9-16. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27789466",
"target":"_blank"
},
"children":[
"PMID: 27789466"
]
},
" doi:10.1136/annrheumdis-2016-210571"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_rm_t22":{
"id":"mk19_b_rm_t22",
"number":22,
"bookId":"rm",
"title":{
"__html":"Extraglandular Clinical Manifestations of Sjögren Syndrome"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"633113",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 22. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t22"
}
]
},
"Extraglandular Clinical Manifestations of Sjögren Syndrome"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f994c",
"class":"col hd l",
"children":[
"Site/Organ"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ccb790",
"class":"col hd l",
"children":[
"Manifestation/Frequency"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0db377",
"class":"cell txt l",
"children":[
"General"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c84666",
"class":"cell txt l",
"children":[
"Fatigue (70%), fever (6%)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"931356",
"class":"cell txt l",
"children":[
"Skin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7a3c84",
"class":"cell txt l",
"children":[
"Dry skin (xerosis), cutaneous vasculitis: 10%-16%"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b14c4e",
"class":"cell txt l",
"children":[
"Joint"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d141a7",
"class":"cell txt l",
"children":[
"Arthralgia/arthritis: 36%"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"efb2b0",
"class":"cell txt l",
"children":[
"Lung"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"83ac43",
"class":"cell txt l",
"children":[
"Interstitial pneumonitis: 5%-9%"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4ff2bb",
"class":"cell txt l",
"children":[
"Kidney"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb1b8e",
"class":"cell txt l",
"children":[
"Interstitial nephritis, type 1 (hypokalemic distal) renal tubular acidosis, glomerulonephritis: 5%-6%"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2bd728",
"class":"cell txt l",
"children":[
"Neurologic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"62e7bb",
"class":"cell txt l",
"children":[
"CNS: demyelinating disease, myelopathy, cranial nerve neuropathy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b21385",
"class":"cell txt l",
"children":[
"Peripheral nervous system: small-fiber neuropathy, mononeuritis multiplex, peripheral neuropathy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7bbaf3",
"class":"cell txt l",
"children":[
"8%-27% for CNS and peripheral nervous system"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef024b",
"class":"cell txt l",
"children":[
"Gastrointestinal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e705cb",
"class":"cell txt l",
"children":[
"Autoimmune hepatitis, primary biliary cirrhosis: 3%-20%"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"20042c",
"class":"cell txt l",
"children":[
"Hematologic"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"24b137",
"class":"cell txt l",
"children":[
"Lymphoma, cytopenia: 2%"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6311ae",
"class":"cell txt l",
"children":[
"Other"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b7e93b",
"class":"cell txt l",
"children":[
"Systemic vasculitis (7%), cryoglobulinemia (4%-12%), Raynaud phenomenon (16%), thyroid disease (10%-15%)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CNS = central nervous system."
]
]
},
"mk19_b_rm_t23":{
"id":"mk19_b_rm_t23",
"number":23,
"bookId":"rm",
"title":{
"__html":"American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren Syndrome<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"77e161",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 23. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t23"
}
]
},
"American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren Syndrome",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"2"
},
"children":[
" ",
{
"type":"p",
"hlId":"61f516",
"class":"col hd l",
"children":[
"Presence of subjective finding of Sjögren syndrome (e.g., sicca) plus any combination of the following resulting in a score of ≥4:"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7d74f3",
"class":"col hd l",
"children":[
"Item"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5dd135",
"class":"col hd l",
"children":[
"Score"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6b72f",
"class":"cell txt l",
"children":[
"Salivary gland biopsy specimen showing ≥1 foci of lymphocytic infiltrate/4 mm",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"717424",
"class":"cell txt l",
"children":[
"Anti-Ro/SSA autoantibodies"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eccbc8",
"class":"cell txt l",
"children":[
"3"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ec3528",
"class":"cell txt l",
"children":[
"Ocular staining score ≥5 in at least one eye"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7b35a8",
"class":"cell txt l",
"children":[
"Schirmer test ≤5 mm/5 min in at least one eye"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"798f00",
"class":"cell txt l",
"children":[
"Unstimulated whole saliva flow rate ≤0.1 mL/min"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Exclusion criteria include prior head/neck radiation and history of active hepatitis C virus infection, AIDS, sarcoidosis, amyloidosis, graft-versus-host disease, and IgG4-related disease."
],
[
"From Shiboski CH, Shiboski SC, Seror R, et al; International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017 Jan;69(1):35-45. doi:10.1002/art.39859. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27785888",
"target":"_blank"
},
"children":[
"PMID: 27785888"
]
},
". Copyright 2016, American College of Rheumatology. Adapted with permission from John Wiley & Sons, Inc."
]
]
}
}
}